CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
3.040
-0.220 (-6.75%)
Apr 28, 2026, 4:00 PM EDT - Market closed
CEL-SCI Market Cap
CEL-SCI has a market cap or net worth of $24.60 million as of April 29, 2026. Its market cap has increased by 4.25% in one year.
Market Cap
24.60M
Enterprise Value
27.42M
1-Year Change
4.25%
Ranking
Category
Stock Price
$3.04
Market Cap Chart
Since December 1, 1998, CEL-SCI's market cap has decreased from $27.40M to $24.60M, a decrease of -10.21%. That is a compound annual growth rate of -0.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 28, 2026 | 25.70M | -41.86% |
| Dec 31, 2025 | 44.20M | 79.67% |
| Dec 31, 2024 | 24.60M | -81.90% |
| Dec 29, 2023 | 135.90M | 32.46% |
| Dec 30, 2022 | 102.60M | -66.58% |
| Dec 31, 2021 | 307.00M | -33.78% |
| Dec 31, 2020 | 463.60M | 43.22% |
| Dec 31, 2019 | 323.70M | 297.18% |
| Dec 31, 2018 | 81.50M | 226.00% |
| Dec 29, 2017 | 25.00M | 96.85% |
| Dec 30, 2016 | 12.70M | -73.60% |
| Dec 31, 2015 | 48.10M | -9.42% |
| Dec 31, 2014 | 53.10M | 80.61% |
| Dec 31, 2013 | 29.40M | -60.16% |
| Dec 31, 2012 | 73.80M | 10.81% |
| Dec 30, 2011 | 66.60M | -60.45% |
| Dec 31, 2010 | 168.40M | 25.11% |
| Dec 31, 2009 | 134.60M | 300.60% |
| Dec 31, 2008 | 33.60M | -42.37% |
| Dec 31, 2007 | 58.30M | 27.85% |
| Dec 29, 2006 | 45.60M | 25.27% |
| Dec 30, 2005 | 36.40M | -15.74% |
| Dec 31, 2004 | 43.20M | -37.39% |
| Dec 31, 2003 | 69.00M | 845.21% |
| Dec 31, 2002 | 7.30M | -67.12% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lisata Therapeutics | 28.18M |
| Neuphoria Therapeutics | 27.76M |
| Lantern Pharma | 27.57M |
| NanoViricides | 26.99M |
| ABVC BioPharma | 26.69M |
| NeuroSense Therapeutics | 26.53M |
| Longeveron | 26.35M |
| AEON Biopharma | 26.32M |